A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway

Tumor-initiating cell (TIC) is a subpopulation of cells in tumors that are responsible for tumor initiation and progression. Recent studies indicate that hepatocellular carcinoma-initiating cells (HCICs) confer the high malignancy, recurrence and multi-drug resistance in hepatocellular carcinoma (HCC). In this study, we found that Icaritin, a prenylflavonoid derivative from Epimedium Genus, inhibited malignant growth of HCICs. Icaritin decreased the proportion of EpCAM-positive (a HCICs marker) cells, suppressed tumorsphere formation in vitro and tumor formation in vivo. We also found that Icaritin reduced expression of Interleukin-6 Receptors (IL-6Rs), attenuated both constitutive and IL-6-induced phosphorylation of Janus-activated kinases 2 (Jak2) and Signal transducer and activator of transcription 3 (Stat3), and inhibited Stat3 downstream genes, such as Bmi-1 and Oct4. The inhibitory activity of Icaritin in HCICs was augmented by siRNA-mediated silencing of Stat3 but attenuated by constitutive activation of Stat3. Taken together, our results indicate that Icaritin is able to inhibit malignant growth of HCICs and suggest that Icaritin may be developed into a novel therapeutic agent for effective treatment of HCC.

[1]  W. Janzen,et al.  High Throughput Screening , 2016, Methods in Molecular Biology.

[2]  N. Sakamoto,et al.  New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  Y. Li,et al.  A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants. , 2015, Carcinogenesis.

[4]  Guangsen Zhang,et al.  Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3 , 2015, Oncotarget.

[5]  T. Tung,et al.  Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression , 2015, Clinical Cancer Research.

[6]  A. Chinnaiyan,et al.  Cisplatin Induces Bmi­1 and Enhances the Stem Cell Fraction in Head and Neck Cancer , 2015 .

[7]  Chin Wee Tan,et al.  Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt–β-catenin–mediated intestinal tumor growth and regeneration , 2014, Science Signaling.

[8]  D. Ma,et al.  Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer , 2014, Oncotarget.

[9]  A. von Deimling,et al.  Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR , 2014, Oncotarget.

[10]  Jia-Bin Huang,et al.  Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma , 2013, PloS one.

[11]  Kristen Jepsen,et al.  Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.

[12]  Wenlong Lv,et al.  Icaritin Synergistically Enhances the Radiosensitivity of 4T1 Breast Cancer Cells , 2013, PloS one.

[13]  Q. Ye,et al.  MicroRNA‐26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin‐6‐Stat3 pathway , 2013, Hepatology.

[14]  G. Sethi,et al.  Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. , 2013, Biochimica et biophysica acta.

[15]  J. Bromberg,et al.  Targeting the interleukin-6/Jak/stat pathway in human malignancies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Tang,et al.  Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine‐treated HBx transgenic mice , 2012, Hepatology.

[17]  Kuen-Feng Chen,et al.  Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. , 2011, Journal of hepatology.

[18]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[19]  Kun Meng,et al.  Icaritin Shows Potent Anti-Leukemia Activity on Chronic Myeloid Leukemia In Vitro and In Vivo by Regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT Signalings , 2011, PloS one.

[20]  I. Ng,et al.  CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. , 2011, Cell stem cell.

[21]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[22]  Xintian Zhang,et al.  An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. , 2011, European journal of pharmacology.

[23]  Qing-Yuan Sun,et al.  Icaritin Causes Sustained ERK1/2 Activation and Induces Apoptosis in Human Endometrial Cancer Cells , 2011, PloS one.

[24]  P. Lu,et al.  Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4–AKT–ATP‐binding cassette G2 pathway , 2010, Hepatology.

[25]  Wei Zhao,et al.  The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. , 2010, Carcinogenesis.

[26]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[27]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[28]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[29]  L. Lin,et al.  The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling , 2009, Oncogene.

[30]  D. Yeung,et al.  A novel semisynthesized small molecule icaritin reduces incidence of steroid-associated osteonecrosis with inhibition of both thrombosis and lipid-deposition in a dose-dependent manner , 2008, Bone.

[31]  A. Iwama,et al.  The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. , 2008, Cancer research.

[32]  Y. Lou,et al.  Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells , 2008, Journal of cellular biochemistry.

[33]  C. Deng,et al.  Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling , 2008, Proceedings of the National Academy of Sciences.

[34]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[35]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[36]  I. Ng,et al.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells. , 2007, Gastroenterology.

[37]  Y. Lou,et al.  Neuroprotective effects of icaritin against beta amyloid-induced neurotoxicity in primary cultured rat neuronal cells via estrogen-dependent pathway , 2007, Neuroscience.

[38]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[39]  Xin-Yuan Fu,et al.  Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor. , 2006, Cancer research.

[40]  N. Maitland,et al.  Prospective identification of tumorigenic prostate cancer stem cells. , 2005, Cancer research.

[41]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[42]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[44]  P. Kerbrat,et al.  [Nonsurgical treatment of hepatocellular carcinoma]. , 1999, Bulletin du cancer.

[45]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[46]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[47]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.